1 recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
Follow Caspofungin: new trials by email Literature Review of Caspofungin trials Research Report on Caspofungin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia Caspofungin Acetate 50 MG, Physiologic saline - Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection | Phase 1 / Phase 2 | Recruiting | University Hospital, Tours | 100 | 2025-12-02 | 2026-10-09 |
| Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients F901318, Caspofungin - Pulmonary Aspergillosis - Invasive, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | F2G Ltd | 2017-04-20 | 2018-02-15 |
Invasive Pulmonary Aspergillosis (1) · Leukemia, Myeloid, Acute (1) · Lung Diseases, Interstitial (1) · Pneumocystis Infections (1) · Pneumonia, Pneumocystis (1) · Respiratory Aspiration (1)
F2G Ltd (1) · University Hospital, Tours (1)
France (1)
PMID 16304338, PMID 18046534, PMID 20946413, PMID 22548840, PMID 23940606, PMID 26935726, PMID 30776290, PMID 31548210, PMID 31633150, PMID 32194238, PMID 41151592, PMID 9872631
2023 (1)